Age but not Philadelphia positivity impairs outcome in older/elderly patients with acute lymphoblastic leukemia in Sweden. (14th June 2017)

• Record Type: Journal Article
• Authors: Kozlowski, Piotr; Lennmyr, Emma; Ahlberg, Lucia; Bernell, Per; Hulegårdh, Erik; Karbach, Holger; Karlsson, Karin; Tomaszewska‐Toporska, Beata; Åström, Maria; Hallböök, Heléne
• Is Part Of: European journal of haematology. Volume 99:Number 2(2017)
• Page Start: 141
• Page End: 149
• Publication Date: 2017-06-14
• Subjects: acute lymphoblastic leukemia -- chemotherapy -- elderly -- epidemiology; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.12896
• Languages: English
• ISSNs: 0902-4441

Abstract

Abstract: Objectives: Older/elderly patients with acute lymphoblastic leukemia (ALL) are poorly represented in clinical trials. Methods: Using Swedish national leukemia registries, we investigated disease/patient characteristics, treatment choices, outcome, and the impact of an age‐adapted protocol (introduced in 2009) in this population‐based study of patients aged 55‐85 years, diagnosed with ALL 2005‐2012. Results: Of 174 patients, 82% had B‐phenotype, 11% Burkitt leukemia (excluded), and 7% T‐phenotype. Philadelphia chromosome positivity (Ph+) occurred in 35%. Of the 155 B‐ and T‐ALL patients, 80% were treated with intensive protocols, and 20% with a palliative approach. Higher age and WHO performance status ≥2 influenced the choice of palliation. Intensive, palliative, and both approaches resulted in complete remission rate 83/16/70% and 3‐year overall survival (OS) 32/3/26%. The age‐adapted protocol did not improve outcome. With intensive treatment, platelet count ≤35×10 9 /L and age ≥75 years were adverse prognostic factors for OS, Ph+ was not. Male sex was an adverse prognostic factor in the 55‐64 year age‐group. Conclusions: We report a high frequency of Ph+ in older/elderly patients, with no evidence of poorer outcome compared to Ph‐negative disease. Overall prognosis for elderly patients with ALL remains dismal, despite the use of age‐adapted treatment.